Almac | GenomeWeb


The partners plan to develop a computational platform that automates pipelines and processes for biomarker discovery, drug recovery and repositioning, and more.

The deal allows UK-based Almac to develop NGS assays on the Illumina MiSeqDx instrument.

The firms are developing a gene expression RSPO3 CLIA assay to select patients in the clinical development of OncoMed's therapeutic.

NEW YORK (GenomeWeb) — Pharmaceutical companies are jockeying to formulate companion diagnostics strategies that involve a new microarray-based assay developed by Almac Diagnostics, according to the company.

NEW YORK (GenomeWeb) — Almac Diagnostics has developed a microarray-based test that can be used to determine which ovarian cancer patients will have a good prognosis following chemotherapy.

NEW YORK (GenomeWeb News) – Almac's diagnostics business today said that it has received a clinical laboratory permit from New York, allowing it to receive clinical samples from the state for clinical testing and trial management.

Almac Diagnostics said this week that a group led by partner Precision Therapeutics has independently validated Almac's ColDx test for stage II colorectal cancer recurrence ahead of its full commercialization in the US.

A new assay that can be used to gauge a breast cancer patient's response to chemotherapy is described in a new Journal of the National Cancer Institute paper.

NEW YORK (GenomeWeb News) – Almac today said that its biocatalysis group and University College London will jointly work on a project to develop tools aimed at metagenomics and novel enzyme discovery.


In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.